Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF SEPTEMBER 25, 2016 FBO #5420
DOCUMENT

65 -- Oncotype DX® Breast Cancer Assay cost per test reportable - Attachment

Notice Date

9/23/2016
 

Notice Type

Attachment
 

NAICS

621511 — Medical Laboratories
 

Contracting Office

Department of Veterans Affairs;G.V. (Sonny) Montgomery VAMC;1500 E. Woodrow Wilson Dr.;Jackson MS 39216
 

ZIP Code

39216
 

Solicitation Number

VA25616Q1547
 

Response Due

9/26/2016
 

Archive Date

12/25/2016
 

Point of Contact

DIYONNE WILLIAMS
 

E-Mail Address

diyonne.williams@va.gov
(diyonne.williams@va.gov)
 

Small Business Set-Aside

Total Small Business
 

Description

Oklahoma City VA Medical Center Oklahoma City, OK 73104 STATEMENT OF WORK FOR ONCOTYPE DX ® BREAST CANCER ASSAY I.Introduction The Oklahoma City VA Medical Center (OKC VAMC) Pathology and Laboratory Service intends to pursue an IDIQ contract for the provision of Oncotype DX ® Breast Cancer Assay. The Oncotype DX ® Breast Cancer Assay provides personalized information based on tumor biology that can inform treatment decisions that are cost effective. The Oncotype DX ® Breast Cancer Assay was developed by and is proprietary to Genomic Health, Inc. The Assay is clinically validated to predict the risk of recurrence for those women with early stage (I, II, IIIa) invasive breast cancer that are estrogen-receptor positive (ER+), human epidermal growth factor receptor negative (Her2-), lymph node negative or positive and predict who may or may not significantly benefit from adjuvant chemotherapy. The Oncotype CX ® Breast Cancer Assay is standard of care and has been incorporated in the clinical guidelines of the American Society of Clinical Oncology and the National Comprehensive Cancer Network. Item DescriptionIMF #Unit/IssueVendor Stock # ONCOTYPE DX BREAST CANCERN ASSAY S38546 EACPT s3854 II.Statement of Work Contractor shall: 1.Be College of American Pathologist (CAP) accredited. 2.Hold current Clinical Laboratory Improvement Act (CLIA) certification for high complexity testing. 3.Provide requisitions and any required specialized specimen collection ortransport materials. 4.Perform Oncotype DX ® Breast Cancer Assay on tissues sent. 5.Provide hard copy results to laboratory when available. 6. Deliver products to 921 NE 13th Street, Oklahoma City, OK upon request from Pathology and Laboratory VAMC Oklahoma City Point of Contact. (the point of contact will be identified after award) III.Performance Period. Date of award to September 30, 2017.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/JaVAMC/VAMCCO80220/VA25616Q1547/listing.html)
 

Document(s)

Attachment
 

File Name: VA256-16-Q-1547 VA256-16-Q-1547.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=3022372&FileName=VA256-16-Q-1547-000.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=3022372&FileName=VA256-16-Q-1547-000.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Record

SN04286108-W 20160925/160923235000-4e0ce156a14a3a010238bc80bfb12d5d (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |